UCB (STU:UNC) Short Percentage of Float


STU:UNC UCB SA STU:UNC
90 GF Score
Price €264.40
GF Value €213.09
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:UNC vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, UCB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where UCB's Short Percentage of Float falls into.


STU:UNC
90GF Score
UCB SA STU:UNC
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €264.40 is trading 24.1% above its estimated GF Value™ of €213.09. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Short Percentage of Float:
  • GF Value™: €213.09 vs. price of €264.40 (24.1% above fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score

Get the complete analysis for STU:UNC

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€264.40
Price
€213.09
GF Value